EXJADE offers simple and convenient dosing for your patients compared with previous formulations.^1–3

is taken once-daily^1,2

does not contain lactose or sodium lauryl sulphate²

can be taken on an empty stomach or with a light meal^1,2

should be swallowed whole or may be fully crushed^*1,2

 

 

*If crushed, tablets must be immediately and completely consumed.

EXJADE may be used for the treatment of:

Transfusional iron overload in patients with MDS, SCD and thalassaemia^1,2

MDS, SCD and thalassaemia are a group of blood disorders that can lead to anaemia as a result of a deficiency in Hb or healthy RBCs in the blood. Repeated blood transfusions can be used as a treatment in order to prevent this deficiency, however this can lead to the build-up of excess iron known as iron overload.⁴

Iron overload in patients with non-transfusional thalassaemia^1,2

Patients with non-transfusion-dependent thalassaemia syndromes have a heightened absorption of dietary iron. This takes place within the GI tract and is a cause of iron overload.⁴

It is important to control levels of excess iron in order to avoid the toxic effects of iron build-up. This can be achieved using medications known as iron chelators, such as EXJADE. EXJADE has the ability to bind to excess iron to form an iron-complex. This complex can then be easily excreted and removed by the body.⁴

Please refer to the SmPC for the licensed indication and further information.

EXJADE is available as a simplified, convenient, once-daily FCT^1,2

EXJADE FCT is available in 3 strengths:²

This range in tablet strength allows for iron-overloaded patients to have a dose tuned to their needs.

Dosing schedule and dose adjustment steps vary depending on indication. The recommended dosing schedules for patients with transfusional iron overload and non-transfusion-dependent thalassaemia syndromes are available on this website and can be viewed via the links below or via the SmPC.

Abbreviations: FCT, film-coated tablets; GI, gastrointestinal; Hb, haemoglobin; ICT, iron chelation therapy; MDS, myelodysplastic syndromes; RBC, red blood cell; SCD, sickle cell disease; SmPC, Summary of Product Characteristics.

References

1. EXJADE^® dispersible tablets summary of product characteristics.
2. EXJADE^® film-coated tablets summary of product characteristics.
3. Taher A, et al. New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, Phase II ECLIPSE study. Am J Hematol 2017;92(5):420–428.
4. Cappellini MD, et al. Guidelines for the management of transfusion dependent thalassaemia (TDT). 3^rd ed. Nicosia, Cyprus: Thalassaemia International Federation; 2014.